THERAVANCE BIOPHARMA INC (TBPH)
Health Care · Respiratory / COPD therapeutics · NASDAQ
A commercial-stage biopharmaceutical company with an FDA-approved COPD inhalation therapy under review for strategic alternatives following a failed neurology pipeline program.
What THERAVANCE BIOPHARMA INC does
Theravance Biopharma is a biopharmaceutical company focused on developing and commercializing medicines. The company's primary product is YUPELRI (revefenacin) inhalation solution, an FDA-approved treatment for chronic obstructive pulmonary disease (COPD), which it co-promotes with Viatris in the US. The company is currently undergoing a strategic review to evaluate value-maximizing alternatives following the failure of its ampreloxetine Phase 3 clinical trial.
Themes: ["COPD treatment","Respiratory medicine","Inhalation therapeutics"]
Fundamentals
- Price$16.98 as of 2026-07-09 close
- Market cap$881M as of 2026-07-10
- 1-year return+46.5% as of 2026-07-09 close
- P/E7.69 as of 2026-07-10
- Net margin+104.3% as of 2026-07-10
- Gross margin+100.0% as of 2026-07-10
- ROE+43.9% as of 2026-07-10
- Debt / equity0.11 as of 2026-07-10
- Revenue growth (YoY)+68.2% as of 2026-07-10
- Revenue CAGR (3y)+27.9% SEC XBRL
- Beta0.25 as of 2026-07-10
Key risks (from latest filing)
["YUPELRI market acceptance and pricing pressure: Physician and payor adoption may not grow as planned; the product faces pricing headwinds from channel mix evolution and lower realized net prices, which could materially harm revenue","Sales and marketing execution risk: Maintaining an effective US sales force and obtaining prescriber access for YUPELRI, particularly in hospital settings, is costly and operationally challenging","Strategic review uncertainty: The ongoing evaluation of strategic alternatives (including a potential sale) may not result in a favorable transaction or outcome, and the process itself could adversely affect the business"]
Competitors & peers
- Boehringer Ingelheim (tiotropium, COPD inhalers)
- Novartis (Seebri, COPD)
- GlaxoSmithKline (Anoro, COPD inhalers)
- AstraZeneca (Symbicort, Pulmicort, COPD)
- Viatris (YUPELRI co-promoter, also direct competitor in bronchodilators)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.